【barrettes that don't break hair】Aurobindo Pharma to recall 80 lots of blood pressure medicine valsartan in the US
Jan 2 (Reuters) - A U.S. unit of Indian generic drugmaker Aurobindo Pharma Ltd will recall 80 lots of medicines containing blood pressure drug valsartan that were found to have a probable cancer-causing impurity,barrettes that don't break hair according to the U.S. Food and Drug Administration.
The impurity N-Nitrosodiethylamine (NDEA) was detected in quantities above the acceptable limit in certain tablets containing valsartan, the FDA said.
The announcement comes a month after Mylan NV said it will recall all lots of its blood pressure medicines containing valsartan, an angiotensin II receptor blocker, after global health authorities clamped down on the drug.
The health regulator said it will continue to investigate and test all angiotensin II receptor blockers for the presence of NDEA and another probable carcinogen N-nitrosodimethylamine.
In October last year, the FDA halted imports of drug ingredients or medicines containing ingredients produced at a factory of a Chinese bulk manufacturer of valsartan, Zhejiang Huahai Pharmaceuticals.
(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shinjini Ganguli)
View comments
下一篇:The Zacks Analyst Blog Highlights: Telenav, Forestar, Alpine Income Property Trust, Innovative Industrial Properties and MDU Resources
相关文章:
- Gilead Sciences Could Be the First to Beat the Coronavirus
- Shop Samsung deals on smartphones, TVs, accessories and more for the new year
- Earnings Preview: Macy's to report 3Q profits
- What Kind Of Shareholders Own CWT International Limited (HKG:521)?
- Lam Research unveils improved tool to make 3-D chips for phones, devices
- AMWD vs. WSC: Which Stock Should Value Investors Buy Now?
- The Latest: Ariz. gov. rejects call for online learning
- Our Take On XPD Soccer Gear Group Limited’s (ASX:XPD) CEO Salary
- Ramping up COVID-19 testing earlier would have helped the UK, top adviser says
- Is There More To Minda Corporation Limited (NSE:MINDACORP) Than Its 14% Returns On Capital?
相关推荐:
- Is Sirius International Insurance (SG) A Good Stock To Buy Now?
- Resolutions 2019: Crush Your Debt in 3 Simple Steps
- This Might Be the Most Frustrating Round of Wheel of Fortune Ever
- Study finds that Vermont is top state for inbound moves
- Coronavirus to have substantial impact on trade: WTO
- Axiom Prepaid Holdings Caps Off Banner Year with a Prestigious Accolade for Its CEO
- UK abolishes 'sexist' tax on women's sanitary products
- Do Insiders Own Shares In Alcidion Group Limited (ASX:ALC)?
- Is MYR Group (MYRG) a Great Value Stock Right Now?
- Morning News Call - Canada, January 2
- Microsoft Is in Talks to Buy TikTok in U.S.
- Trump calls for shift in coronavirus strategy to allow for end to lockdowns
- Upstate New York could be getting a Soho House
- Callon Petroleum Climbs 4% As 3Q Sales Surge 74%; Street Sticks To Hold
- Sun Summit Minerals Phase 2 Drilling Update and Completion of IP Survey at the Buck Property
- Spa chain secured $5.6M in coronavirus relief for small businesses despite losses last year
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesa Air Group, Inc. - MESA
- Outlook into the Worldwide Plasma Protein Therapeutics to 2025 - Featuring CSL Behring, Biotest AG & Baxter Among Others
- HSBC adds former co-CEO of world's biggest hedge fund Bridgewater Associates to board
- UPLCQ Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Ultra Petroleum Corp. Investors of Class Action and Lead Plaintiff Deadline: November 2, 2020